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Health care policyAbstract Background: Currently, the Council of Cooperative Health Insurance (CCHI) is the
body responsible for regulating health insurance in the KSA. While the cooperative health insur-
ance schedule (i.e., model policy for health insurance) is available on the CCHI web site, policies
related to pharmaceuticals are ambiguous.
Aims: The primary objective of this study was to assess the impact of health insurance policies
provided by health insurance companies in KSA on access to medication and its use.
Settings and Design: This study was descriptive in design and used a survey, which was con-
ducted through face-to-face interviews with the medical managers of health insurance companies.
Methods and Material: The survey took place between March and June, 2011. All 25 insurance
companies accredited by CCHI were eligible to be included in the study. Out of these 25 companies,
three were excluded from this survey as no response was received.
Results: All the 16 companies responded ‘‘Yes’’ that they had a prior authorization policy; how-
ever, their reasons varied. Eight (50%) of the companies were concerned about the duration of
treatment. While 10 (62.5%) did not offer additional coverage over the CCHI model policy, the
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268 S.A. Bawazir et al.other 6 (37.5%) reported that they could reconcile certain conditions. The survey also demonstrated
that 10 insurance companies allowed reﬁlling of medication but with certain limitations. Six out of
the 10 permitted reﬁlling within a maximum time of three months, whereas the other four compa-
nies did not have any time-based limits for reﬁlling. The other six companies did not allow reﬁlling
without prescription.
Conclusions: Although this paper was primarily descriptive, the ﬁndings revealed a substantial
scope for improvement in terms of pharmaceutical policy standards and regulation in the health
insurance companies in KSA. Additionally, the study highlighted such areas to augment the overall
quality use of medication, over-prescribing and irrational use of medication. Further research, thus,
is deﬁnitely needed.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The healthcare system in the Kingdom of Saudi Arabia
(KSA) ensures free medical coverage to all citizens and
expatriates working in the public sector. Under Saudi law,
Saudi citizens are entitled to free healthcare. Private-sector
employees receive basic healthcare coverage from their
employers in the form of insurance policies issued by private
insurance companies (Walston et al., 2008). In Saudi Arabia,
which had an estimated population of 27 million in 2010,
healthcare is delivered by three major providers: the network
of hospitals and primary healthcare centers of the ministry
of health (MOH); governmental institutions, such as
National Guard, Military and Security Forces hospitals;
and the private sector. According to recent statistics from
the MOH, KSA has a total of 408 hospitals: 244 hospitals
are part of the MOH network, 39 hospitals belong to
governmental institutions, and 125 belong to the private
sector (Central Department of Statistics and Information,
2010; MOH, 2011).
The private health insurance system in Saudi Arabia was
the result of the implementation of the Health Insurance Act
in 1999. This act aims to control and regulate the provision
of health insurance for both Saudi and non-Saudi residents
in the Kingdom. The Council of Cooperative Health Insurance
(CCHI) is an independent government body established to reg-
ulate the health insurance industry in the Kingdom (MOH,
2011).
As stated in article 17 of Health Insurance Act, health
insurance can be offered by qualiﬁed Saudi insurance compa-
nies. Currently, the CCHI has accredited and approved 25
insurance companies. Additionally, the CCHI has issued6
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re-authorization.licenses to ﬁve third party administrators (TPAs) and more
than 2150 health care providers (CCHI, 2011).
A model health insurance policy is available on the CCHI
website. The beneﬁts and limitations of coverage under the
CCHI model policy is SR 250,000 ($66,667) per person annu-
ally. The coverage is inclusive of services such as consultation,
laboratory tests, X-rays, medicines, and other medical necessi-
ties as well as follow-up visits and referral for the same illness.
Other hospitalization and medical expenses, such as those re-
lated to pregnancy and delivery, premature babies, cost of den-
tal treatment, spectacles, renal dialysis, and acute
psychological disorders, are subject to certain maximum limits
during the term of policy. For example, the maximum cover-
age for acute psychological disorders is SR 15,000 ($4000) dur-
ing the term of the policy.
Additionally, the CCHI (CCHI, 2011) has issued general
exclusions from the model policy, and conditions related to
treatment are summarized as follows:
1. Treatment of any condition as a result of alcohol or
drug abuse.
2. General health examinations, vaccinations and/or pro-
phylactic (except which stated by MOH, such as children
vaccination etc.).
3. Management of Human Immune Deﬁciency Virus
(AIDS).
4. Treatment of any sexually transmitted disorder (STD).
5. Treatment for cosmetic purposes.
6. Chronic psychological disorders.
7. Treatment of hair fall.
8. Birth control pills.
9. Any treatment connected with fertility and/or sterility
and/or impotence and/or contraception and/or hor-
monal treatment.
10. Management of acne and obesity.
11. Herbal or dietary supplements.
According to the World Health survey data, about half (41–
56%) of individuals in low and middle-income countries spend
all of their health care expenditures on medicines (Wagner
et al., 2011). Recommendations from the second International
Conference on Improving Use of Medicines (2004) concluded
that the insurance system has a great potential to augment the
use of medicines (ICIUM, 2004). In the CCHI model schedule,
although medication expenses are covered up to a maximum
annual limit of SR 250,000 ($66,667) per person, policies re-
lated to prescription drugs, such as reﬁlls and pre-authoriza-
tion for service, are not clearly deﬁned. This paper aims to
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health insurance companies in KSA on access to medication
and its use.
2. Subjects and methods
A questionnaire was used as the main tool of data collection in
this study. The questionnaire was developed to cover both the
insurance industry and the medication coverage policy. Two
qualiﬁed pharmacists from Saudi Food and Drug Authority
(SFDA) were involved in posing the questions of the question-
naire. The questionnaire can be found in Appendix 1.
All 25 companies accredited and listed by CCHI were eligi-
ble to be included in the study. Out of these 25 companies,
three were excluded from this survey, as they did not respond
to the survey request. Further, seven of the remaining compa-
nies were represented by a TPA and offered identical insurance
policies. Thus, the total number of the companies enlisted in
the survey was 16.
The questionnaire was administered through face-to-face
interviews with the medical managers of health insurance com-
panies. The survey took place between March and June, 2011.
The interview was conducted at the company site or at SFDA.
Eight of the 22 companies submitted their completed surveys
via email and clariﬁcations, if needed, were sought through
phone calls. Owing to prior agreement, the names of the insur-
ance companies have been anonymous.
3. Results
3.1. An overview of insurance companies
In the ﬁrst part of the questionnaire, seven questions were de-
signed to gain an overview of the health insurance companies
operating in Saudi Arabia. Citing reasons of conﬁdentiality,two of the surveyed companies did not respond to the ﬁrst
part. Thus, a total of 14 companies answered the ﬁrst part of
the questionnaire.
The ﬁrst question pertained to the core insurance business
of the companies. Seven of the 14 companies conﬁrmed that
health insurance is their core business. The companies were
then asked to enumerate their staff numbers in 2009. Nine
companies had more than 100 employees and the TPA com-
pany, which managed seven health insurance companies, had
more than 100 employees. After that, the percentage of the
company’s business of health insurance showed that 77% of
the companies fall between 20% and 60%. Table 1 shows
the percentage of health insurance and the number of compa-
nies that fall in this range.
As the companies had different terminologies and prices for
the different types of health insurance they offered, direct
assessment and comparison of the policies was not possible.
With regard to the maximum annual beneﬁt limit per year,
14 companies did not have any maximum limit to drug cover-
age while two others did not respond. Data collected to deter-
mine the number of individuals covered under health insurance
in 2009 and 2010 showed that, among 14 companies, more
than 5.36 million individuals were covered by private health
insurance in 2010, as opposed to more than 3.97 millions in
2009.
Table 2 Inclusion or exclusion of drug coverage.
Who makes the decision Company(s)a
CCHI model policy 6
Medical committee 4
Health services provider 4
Physician at the company 4
Pharmacist at the company 1
a Companies could select more than one option.
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The second part of the questionnaire examined policies related
to accessing medications. All the 16 companies replied to all
the questions in the second part. Results of the 13 questions,
in the second part, are detailed as follows:
The purpose of the ﬁrst question was to determine whether
a company had different coverage policies for individuals
and companies or institutions. None of the surveyed compa-
nies had different coverage policies for individuals and
institutions.
The second question was designed to identify the person/
committee responsible for including or excluding drugs from
coverage at the insurance company. Some companies selected
more than one option. Table 2 illustrates that 50% of the
insurance companies follow the CCHI model policy.
In the third question, the aim was to determine whether the
insurance company fully adhered to the CCHI model policy or
whether it was ﬂexible to include its own terms into the policy.
Results showed that 10 (62.5%) companies did not offer addi-
tional coverage over the CCHI model policy. The remaining
six (37.5%) companies offered additional coverage depending
on customer preferences.
The fourth question assessed the insurance company’s
views on drug exceptions (drug not covered). The purpose
was to recognize whether the insurance company refers to
the general exceptions by CCHI or they may have their own
exceptions based on certain justiﬁcations. Eleven out of 22
companies followed the exceptions issued by CCHI, but ﬁve
companies had more exceptions in addition to the ones of
CCHI, such as the use of generic drug instead of branded one.
With regard to prior authorization for drugs (ﬁfth ques-
tion), all the companies conﬁrmed that they had a prior autho-
rization policy but for different reasons. Fifty percent (eight
companies) stated that their main concern was the duration
of treatment (see Graph 1).
The sixth question was related to the ﬁfth: what is the
approximate time taken to receive an approval from the insur-
ance company for a prior authorization? The model policy of
the CCHI stated that, ‘‘the insurance company should convey
the approval request within a period not exceeding sixty min-
utes from the time of receipt of such request.’’ Among the sur-
veyed companies, 87.5% indicated that the time taken to
approve a prior authorization request was few minutes,
whereas 12.5% said that they take 1–2 h for approval.
The seventh question asked the type of professional who re-
views the patient’s prescription. All the companies have a phy-
sician reviewer, 33.3% also had a pharmacist, 33.3%
companies had a nurse, 25% employed dentists, and the
remaining 8.3% companies involved other health professionals
in the review process. Graph 2 shows the distribution.The eighth question was related to the maximum number of
drugs that could be prescribed by a physician during a single
visit. None of the companies had imposed a limit on the num-
ber of drugs per prescription.
Question nine was related to the maximum number of days,
as a base line, for which a drug could be prescribed. The re-
sponses were as follows: 31.25% of the companies had deﬁned
one month as the upper limit; 31.25% allowed a drug to be
prescribed for a maximum of three months; 12.5% chose
two months; 12.5% did not have a maximum limit; and
6.25% indicated one week as the upper limit (see Graph 3).
The tenth question assessed the importance of a drug being
covered or listed in the Saudi National Formulary (SNF). Of
the companies, 18.75% were not concerned about whether a
drug was registered or not. The rest of the companies indicated
their insurance policies only covered registered drugs.
Question eleven pertained to the maximum cost of drugs
that could be prescribed during a single visit. No limits were
placed by 81.25% of the companies, and other companies im-
posed maximum limits for different reasons: less than SR 1000
($267), based on the condition, class of drug, or depending on
the policy.
The twelfth and the thirteenth questions concerned the abil-
ity of patients to reﬁll prescriptions without a doctor visit and
the maximum number of reﬁlls allowed. Ten of the 16 compa-
nies permitted reﬁlling with some limitations: six allowed reﬁll-
ing up to a maximum of three months, whereas the other four
companies did not have time limits. The remaining six sur-
veyed companies did not allow reﬁlling without prescription.
4. Discussion
While medical expenses in the CCHI model policy are subject
to a maximum annual beneﬁt limit per person (i.e., SR 250,000
($66,667)), many issues related to prescription drugs, such as
reﬁlls, quantity, pre-authorization cases etc., are still vague.
It is also not clear if an insurance company can modify the
pharmaceutical terms in a policy or if it must fully follow
the CCHI model policy. A similar ambiguity exists in the case
of general exceptions. This paper, therefore, was carried out to
ascertain the gaps in the current medication coverage autho-
rized by insurance companies in the KSA. Issues can thus be
highlighted and appropriate recommendations generated to
improve the overall quality of medication use. This research
is, to the best of our knowledge, the ﬁrst systematic description
of the private insurance industry in Saudi Arabia.
The overall results indicate that there are inconsistencies in
the pharmaceutical coverage in the health insurance policy.
One relevant example is query number 10 in the second part
of the survey, which asks for the importance of a drug being
listed in the SNF for coverage. The outcomes were contradic-
tory, as demonstrated in the results section. Two leading insur-
ance companies, for instance, reported that registered drugs
are not necessarily included in their system as there is no def-
inite regulation in the CCHI that forces an insurance company
to cover only registered drugs. While there is no such stipula-
tion in the CCHI concerned with registered medications, med-
ical health providers should prescribe registered medications as
per the MOH regulation. According to article number 19 of
the Institutions and Pharmaceutical Products Law cited by
the SFDA, ‘‘consumption and utilization of pharmaceutical
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SFDA’’ (SFDA, 2011). Accordingly, and in light of this regu-
lation, an insurance company should have the right to refuse
the non-approved drugs in Saudi Arabia.
The responses to the ﬁfth question in the second part of the
questionnaire also offer a valuable insight. This question on
prior authorization for medications was included to gain an
understanding of the information that insurance companies
need before they decide to approve a drug. Two factors came
to the fore: The ﬁrst was the duration of intake. If the medica-
tion being prescribed had to be consumed for one month, prior
authorization was required. Some insurance companies, how-
ever, extended this duration to two months or more. This is
possibly to accommodate chronic disorders such as hyperten-
sion and diabetes. The second signiﬁcant aspect was cost. Six
companies reported that if the price of prescribed medication
exceeded SR 500 ($133.3), as a standard, then a pre-authoriza-
tion process was needed. Other factors that were also listed by
insurance companies included cosmetic reasons, drugs with age
limits, and medications excluded under the CCHI. Monitoring
the consumption of all chronic medications was one of the ma-
jor justiﬁcations that led insurance companies to apply the pre-
authorization system. In terms of the prior authorization of
medication prescriptions, we believe that the above inconsisten-
cies are due to the lack of CCHI particular guidelines.
Having discussed these examples with regard to standards
of the pharmaceutical coverage of health insurance policies,
it is important to argue for the maximum limit on the number
of drugs prescribed in a single prescription on a single visit.
Question eight in the second part of our survey dealt with this
matter, and all insurance companies pointed out that there is
no maximum limit for the number of drugs per prescription.
While the majority of insurance companies veriﬁed that this,
basically, depends on the indication as per physician prescrip-
tion, this may lead to the problem of overprescribing. A pilot
study was conducted in Saudi Arabia to examine the prescrib-
ing pattern of ambulatory care physicians. The study revealed
a tendency to overprescribe certain categories of drugs, which
could lead to serious adverse reactions and overdosing (Bawa-
zir, 1993). Further retrospective review in Saudi Arabia identi-
ﬁed the need to rationalize the use of drugs such as simple
analgesics, antipyretics and nonsteroidal anti-inﬂammatory
drugs (NSAIDs) to lessen the serious adverse effects of over-
prescribing (Al-Homrany and Irshaid, 2007). Medical profes-
sionals, working in health insurance companies, play an
important role in verifying the clinical needs of medication
written by medical providers, and thus minimizing the problem
of overprescription.
Even though treatment of the Human Immune Deﬁciency
Virus (AIDS/HIV) patients is listed under general exclusions
by the CCHI, the matter is entirely under the control of the
MOH. In contrast, while treatment of STDs is one of the most
under recognized health problems worldwide, it is listed under
CCHI general exceptions and do not have a prevention pro-
gram run byMOH as in the case of HIV/AIDS. One descriptive
case series reported and recommended that health education,
early diagnosis and treatment, are the core strategies for pre-
venting STDs in Saudi Arabia (Madani, 2006). Management
of obesity is another critical exemption from the CCHI list. Evi-
dence from systematic reviews has demonstrated that obesity is
associated with an elevated risk for most of the major health
problems, including cardiovascular diseases (CVD), diabetesmellitus (DM) and hypertension (Lenz et al., 2009). According
to the World Health Organization (WHO), overweight and
obesity are the ﬁfth leading risks for global deaths, and at least
2.8 million adults die each year because of being overweight or
obese (WHO, 2012). A national epidemiological health survey
conducted in KSA stressed that an aggressive campaign against
obesity is fundamental (Al-Nozha et al., 2005). Chronic psy-
chological disorders, treatment of impotence and management
of acne are other examples of questionable exclusions. We
deem that the omission of such health problems by the CCHI
and health insurance companies is inappropriate from the view-
point of public health. Consequently, an urgent revision of the
exclusion list is required.
Notwithstanding our study did not attempt or design to
compare the Saudi case with similar international bodies or
studies conducted abroad, some international health insurance
systems can be brieﬂy examined as examples. Medicare bene-
ﬁts in the US, which are coordinated by private health insur-
ance and subsidized by the federal government, are divided
into four major categories: Part A (hospital coverage), Part
B (medical insurance), Part C (Medicare advantage plan),
and Part D (prescription drug plans). Medicare Part D offers
outpatient prescription drug coverage through private plans,
and these plans may vary in premiums, deductibles, formulary
design, and the use of management tools. Plans cover both
generic and brand name prescriptions drugs. With respect to
the formulary, all drugs in six categories are protected: antide-
pressants, antipsychotics, anticonvulsants, antiretrovirals
(HIV/AIDS treatment), immunosuppressants and anticancer
drugs. Otherwise, each Medicare drug plan has its own list
of covered prescription drugs, called a plan’s formulary. For
safety and cost reasons, certain cases may require prior autho-
rization including step therapy and quantity limits. This con-
tradicts with the Saudi case (CCHI) as chronic psychological
diseases and treatment of STD are listed under the exclusion
list, whereas these treatments are entirely protected in the US
policy. Further example among European region, France has
a private insurance operated as a complement to the public
insurance system, which aims to supplement cost sharing and
expand beneﬁts. France has a special program to accommo-
date thirty chronic conditions, and thereby eliminating cost
sharing for covered people. Regardless of price, prescription
drugs in French health insurance are covered with ‘‘value-
based’’ design (The Ofﬁcial US Government Site for Medicare,
2012; Lau and Stubbings, 2012; Schoen et al., 2010; Lau et al.,
2011). In Middle East, while the Abu Dhabi experience with
health insurance in United Arab Emirates (UAE) is relatively
similar to CCHI policy, there are more details with respect to
pharmaceutical coverage services as well as further exclusions.
Although the annual maximum limit for the basic healthcare
services is AED 250,000 ($66,667) for every person, 70% of
the cost of medicine is covered up to a maximum of AED
1500 per year provided that the patient settles 30% of the cost
of every prescription. In addition to this, the health insurance
company’s prior approval is required for prescriptions the cost
of which exceeds AED 500. Unexpectedly, treatment and ser-
vices for smoking cessation programs and the treatment of nic-
otine addiction are excluded from basic healthcare services in
Abu Dhabi health insurance authority (Health Authority of
Abu Dhabi, 2012).
We assert that the health insurance system has an essential
role in improving the overall user access to and utilization of
272 S.A. Bawazir et al.pharmaceuticals as well as in health outcomes. A systematic re-
view of current evidence published in 2011 showed that insur-
ance has been associated with increased percentage of
prescriptions truly ﬁlled, reduced probability of gaps in medi-cal treatments, increased use of drugs in patients with chronic
diseases, and enhanced adherence to a prescribed regimen.
This systematic review also stated that some scientiﬁc studies
determined that the level of blood glucose was better con-
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doses per week, whereas patients who suffered from high
blood pressure had an increased possibility of receiving antihy-
pertensive treatment and hence having their blood pressure
controlled (Faden et al., 2011).
This study had three major limitations. First, the responses
to certain questions may be superﬁcial because of the time con-
straints faced by the medical managers of the insurance com-
panies. Second, certain respondents did not provide complete
data because of the conﬁdentiality policies of their insurance
companies; however; this was in relation to the ﬁrst part of
the survey, which was concerned with an overview of health
insurance companies operating in the KSA. Further, as our
purpose was primarily to undertake a descriptive rather than
a comprehensive assessment, this paper provides an opportu-
nity to further explore pharmaceutical coverage by health
insurance companies. This explains the rational of the inability
to collect considerable amount of data.
In conclusion, the ﬁndings addressed a substantial scope for
improvement in terms of the pharmaceutical policy of health
insurance companies in Saudi Arabia. In addition, the study
highlighted such areas to augment the overall quality use of
medication, and thus further research is necessary to assess
the inﬂuence of health insurance policies on access to medica-tion. Proper monitoring and evaluation of CCHI exclusion list
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